BioLineRx Ltd.
BLRX
Rank in Stocks
#29251
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and... BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Share Price
$0.00314174
Last synced: 2026-11-11
Market Cap
$8.37M
Change (1 day)
-0.76%
Change (1 year)
-46.71%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade BioLineRx Ltd. (BLRX)
Category
Healthcare
EPS for BioLineRx Ltd. (BLRX)
EPS as of June 2026 TTM: $0.00
According to BioLineRx Ltd.'s latest financial reports, its current EPS (TTM) is $0.00. At the end of 2025 the company had an EPS of 0.00, an increase over its 2024 EPS of $-0.01.
EPS history for BioLineRx Ltd. from 2010 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | 0.00 | -93.51% |
| 2025 | 0.00 | -93.51% |
| 2024 | $-0.01 | -87.76% |
| 2023 | $-0.06 | 134.70% |
| 2022 | $-0.03 | -36.94% |
| 2021 | $-0.04 | -64.58% |
| 2020 | $-0.12 | -33.33% |
| 2019 | $-0.18 | -14.29% |
| 2018 | $-0.21 | -22.22% |
| 2017 | $-0.27 | -3.57% |
| 2016 | $-0.28 | 0.00% |
| 2015 | $-0.28 | -9.68% |
| 2014 | $-0.31 | -60.26% |
| 2013 | $-0.78 | -35.54% |
| 2012 | $-1.21 | 13.08% |
| 2011 | $-1.07 | -729.41% |
| 2010 | $0.17 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -505,261.29% |
US
|
|
| $-7.07 | 227,964.52% |
US
|
|
| $-5.29 | 170,545.16% |
AU
|
|
| $12.88 | -415,587.10% |
BE
|
|
| $21.56 | -695,583.87% |
NL
|
Questions about BioLineRx Ltd.'s earnings per share (EPS)
What is BioLineRx Ltd.'s earnings per share (EPS)?
BioLineRx Ltd.'s earnings per share (EPS) over the last twelve months is $0.00, as of Jun 2026.
What was BioLineRx Ltd.'s earnings per share (EPS) in 2025?
In 2025, BioLineRx Ltd.'s earnings per share (EPS) was 0.00, compared with $-0.01 in 2024.
How has BioLineRx Ltd.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, BioLineRx Ltd.'s earnings per share (EPS) was highest in 2025 (0.00) and lowest in 2020 ($-0.12).
How does BioLineRx Ltd.'s earnings per share (EPS) compare with similar companies?
BioLineRx Ltd.'s earnings per share (EPS) ($0.00) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.